INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathway In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function Molecular analysis data… Read More
Company’s listing application approved by Nasdaq VICTORIA, BC – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize… Read More
Clairvoyant on target for potential commercialization of psilocybin treatment in 2025 VANCOUVER, BC – Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder (AUD),… Read More
LAVAL, QC – Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), (“Bausch Health” or the “Company”) announced the first public drug plan listings for PrUCERIS® (budesonide) aerosol… Read More
Dr. Devon Greyson, an assistant professor at the UBC Faculty of Medicine’s School of Population and Public Health, has been appointed an Applied Public Health Chair by the Canadian Institutes… Read More
